RxDoctor Payments Data

Judith Zink

Family · Simpsonville, SCNPI 1881760841

Payments from drug & device makers

$4,519in general payments, 2019–2025

Across 99 payments — averaging $45.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • AstraZeneca$726
  • AbbVie$394
  • Pfizer$241
  • Biomerieux Inc$185
  • Amgen$163
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,519 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$36,467
Medicare patients
112
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$49,191
JardianceEmpagliflozin31$31,495
EliquisApixaban29$30,476
RybelsusSemaglutide11$27,384
LinzessLinaclotide14$18,782
XareltoRivaroxaban15$14,918
Albuterol Sulfate HfaAlbuterol Sulfate68$2,168
Gabapentin91$2,004
SynthroidLevothyroxine Sodium20$1,899
Omeprazole156$1,662
Diclofenac Sodium40$1,502
Levothyroxine Sodium173$1,443
Duloxetine Hcl36$1,304
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$1,196
Ezetimibe65$1,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$74$76,57542 claims
Boehringer IngelheimJardiance$23$31,49531 claims
PfizerEliquis$241$30,47629 claims
AbbVieLinzess, Synthroid$394$20,68234 claims
Johnson & JohnsonXarelto$99$14,91815 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$1,443173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →